(Q53342642)

13 May 2018

meta-analysis

0 references

title

Meta-analyses of the effectiveness of erythropoietin for end-stage renal disease and cancer. (English)

1 reference

13 May 2018

0 references

1 reference

1 reference

Marsh WA

1

1 reference

13 May 2018

Rascati KL

series ordinal

2

1 reference

13 May 2018

publication date

1 September 1999

1 reference

13 May 2018

published in

Clinical Therapeutics

1 reference

13 May 2018

volume

21

1 reference

13 May 2018

issue

9

1 reference

13 May 2018

page(s)

1443-55; discussion 1427-8

1 reference

13 May 2018

Treatment of the anemia of chronic renal failure with subcutaneous recombinant human erythropoietin

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2800%2980003-X

7 January 2021

The safety and the efficacy of maintenance therapy of recombinant human erythropoietin in patients with renal insufficiency

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2800%2980003-X

7 January 2021

Recombinant human erythropoietin and the anemia of multiple myeloma

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2800%2980003-X

7 January 2021

Erythropoietin and the myelodysplastic syndrome

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2800%2980003-X

7 January 2021

Erythropoietin for the treatment of anemia of malignancy associated with neoplastic bone marrow infiltration

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2800%2980003-X

7 January 2021

Efficacy of erythropoietin in the myelodysplastic syndromes: a meta-analysis of 205 patients from 17 studies

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2800%2980003-X

7 January 2021

Pharmacoeconomic applications of meta-analysis for single groups using antifungal onychomycosis lacquers as an example

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2800%2980003-X

7 January 2021

Avoiding bias in the conduct and reporting of cost-effectiveness research sponsored by pharmaceutical companies.

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2800%2980003-X

7 January 2021

A method for assessing the quality of a randomized control trial

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2800%2980003-X

7 January 2021

Effect of human erythropoietin derived from recombinant DNA on the anaemia of patients maintained by chronic haemodialysis

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2800%2980003-X

7 January 2021

Treatment of the Anemia of Hemodialysis Patients with Recombinant Human Erythropoietin

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2800%2980003-X

7 January 2021

Effect of recombinant human erythropoietin on the anemia of chronic renal failure

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2800%2980003-X

7 January 2021

Treatment of the anemia of progressive renal failure with recombinant human erythropoietin

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2800%2980003-X

7 January 2021

Recombinant human erythropoietin in anemic patients with end-stage renal disease. Results of a phase III multicenter clinical trial

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2800%2980003-X

7 January 2021

Recombinant human erythropoietin treatment in pre-dialysis patients. A double-blind placebo-controlled trial

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2800%2980003-X

7 January 2021

Correction of anaemia of chronic renal failure with recombinant human erythropoietin: safety and efficacy of one year's treatment in a European multicentre study of 150 haemodialysis-dependent patients

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2800%2980003-X

7 January 2021

The treatment of anemia with low-dose recombinant human erythropoietin

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2800%2980003-X

7 January 2021

Recombinant human erythropoietin: 18 months' experience in hemodialysis patients

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2800%2980003-X

7 January 2021

Experience with low dose intravenous and subcutaneous administration of recombinant human erythropoietin

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2800%2980003-X

7 January 2021

Low-dose recombinant human erythropoietin therapy in chronic hemodialysis patients

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2800%2980003-X

7 January 2021

Treatment of transfusion-dependent anaemia of chronic renal failure with recombinant human erythropoietin. A European multicentre study in 142 patients to define dose regimen and safety profile

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2800%2980003-X

7 January 2021

Double-blind, placebo-controlled study of the therapeutic use of recombinant human erythropoietin for anemia associated with chronic renal failure in predialysis patients. The US Recombinant Human Erythropoietin Predialysis Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2800%2980003-X

7 January 2021

Responsiveness to recombinant erythropoietin therapy in end-stage renal disease. An analysis of the predictive value of several biological measurements, including circulating erythroid progenitors

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2800%2980003-X

7 January 2021

Erythropoietin treatment of anemia associated with multiple myeloma

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2800%2980003-X

7 January 2021

The treatment of anaemia in the myelodysplastic syndromes with recombinant human erythropoietin

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2800%2980003-X

7 January 2021

Treatment of myelodysplastic syndromes with recombinant human erythropoietin.

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2800%2980003-X

7 January 2021

Improvement in anemia by recombinant human erythropoietin in patients with myelodysplastic syndrome and aplastic anemia

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2800%2980003-X

7 January 2021

Treatment of chemotherapy-induced anemia with recombinant human erythropoietin in cancer patients

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2800%2980003-X

7 January 2021

Effect of subcutaneously administered human recombinant erythropoietin on erythropoiesis in patients with myelodysplasia

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2800%2980003-X

7 January 2021

Phase I-II Trial of Erythropoietin in the Treatment of Cisplatin-Associated Anemia

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2800%2980003-X

7 January 2021

Recombinant human erythropoietin for the treatment of anemia in the myelodysplastic syndromes: a clinical and erythrokinetic assessment

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2800%2980003-X

7 January 2021

Cisplatin-associated anaemia treated with subcutaneous erythropoietin. A pilot study

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2800%2980003-X

7 January 2021

Recombinant human erythropoietin for the treatment of chronic anemia in multiple myeloma and squamous cell carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2800%2980003-X

7 January 2021

Erythropoietin treatment of chronic anaemia of cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2800%2980003-X

7 January 2021

Clinical application of recombinant human erythropoietin for treatments in patients with head and neck cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2800%2980003-X

7 January 2021

Effect of subcutaneous recombinant human erythropoietin in cancer patients receiving radiotherapy: preliminary results of a randomized, open-labeled, phase II trial

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2800%2980003-X

7 January 2021

Recombinant human erythropoietin (rHuEPO) for treatment of myelodysplastic syndrome

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2800%2980003-X

7 January 2021

Selecting the language of the publications included in a meta-analysis: is there a Tower of Babel bias?

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2800%2980003-X

7 January 2021

10.1016/S0149-2918(00)80003-X

Identifiers

DOI

1 reference

13 May 2018

1 reference

13 May 2018